2019-03-01
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer
Publication
Publication
Clinical Cancer Research , Volume 25 - Issue 6 p. 1766- 1773
Additional Metadata | |
---|---|
doi.org/10.1158/1078-0432.Ccr-18-1943, hdl.handle.net/1765/116149 | |
Clinical Cancer Research | |
Organisation | Department of Gastroenterology & Hepatology |
Laere, B, Oeyen, S., Mayrhofer, M., Whitington, T., van Dam, P.J., Van Oyen, P., … Dirix, L. (2019). TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 25(6), 1766–1773. doi:10.1158/1078-0432.Ccr-18-1943 |